Biocryst Pharmaceuticals reported $2.5M in Cost of Sales for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Alnylam Pharmaceuticals ALNY:US USD 51.27M 10.15M
Biocryst Pharmaceuticals BCRX:US USD 2.5M 1.12M
Chugai Pharma 4519:JP JPY 212.91B 143.81B
Daiichi Sankyo 4568:JP JPY 97.98B 13.21B
Gilead Sciences GILD:US USD 1.4B 1000K
GlaxoSmithKline GSK:LN GBP 2.18B 209M
Glaxosmithkline GSK:US GBP 2.18B 209M
Intra Cellular Therapies ITCI:US USD 6.79M 938K
Karyopharm Therapeutics KPTI:US USD 1.87M 888K
Neurocrine Biosciences NBIX:US USD 7.7M 1.6M
Novavax NVAX:US USD 181.76M 252.83M
Ptc Therapeutics PTCT:US USD 10.89M 3.12M
Regeneron Pharmaceuticals REGN:US USD 540.6M 222.8M
Roche Holding ROG:VX 8.95B 613M
Sarepta Therapeutics SRPT:US USD 30.8M 9.15M
Ultragenyx Pharmaceutical RARE:US USD 5.32M 3.31M
Vertex Pharmaceuticals VRTX:US USD 283.3M 6.1M
YTE INCY:US USD 53.76M 4.48M